Shopping Cart

Your shopping cart is currently empty

Gap 27

Name: Gap 27
Brand: TargetMol
SKU: TP1333
Price: 48 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Synonyms:

Catalog No. TP1333 Copy Product Info

😃Good

Gap 27 is a peptide(Ser-Arg-Pro-Thr-Glu-Lys-Thr-Ile-Phe-Ile-Ile) derived from connexin 43 that is a selective gap junction blocker.

Cas No. 198284-64-9

Customer service consultation

Pack Size	Price	USA Stock	Global Stock
1 mg	$48	In Stock	In Stock
5 mg	$97	In Stock	In Stock
10 mg	$141	In Stock	In Stock
25 mg	$236	In Stock	In Stock
50 mg	$352	In Stock	In Stock
100 mg	$528	In Stock	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:>99.99%

Appearance:solid

Color:White

Resource Download

COA

Product Introduction

Bioactivity

Description	Gap 27 is a peptide(Ser-Arg-Pro-Thr-Glu-Lys-Thr-Ile-Phe-Ile-Ile) derived from connexin 43 that is a selective gap junction blocker.
In vitro	Gap 27 significantly reduces the population of TRAP-positive mononuclear and multinucleated rat osteoclasts on bovine bone slices and decreases the functionality of remaining osteoclasts, as demonstrated by a lower percentage of osteoclasts displaying actin rings among all TRAP-positive cells. Moreover, the area resorbed by these treated cultures is substantially reduced[1]. When applied to the carotid artery, Gap 27 at a concentration of 500 μM effectively eliminates the hyperpolarization response to acetylcholine, but does not affect the response to levcromakalim, indicating a specific inhibition of acetylcholine-induced, endothelium-dependent hyperpolarizations in the guinea-pig-isolated internal carotid artery[2].
In vivo	Gap 27 (300 μM) inhibits relaxation by 40% in thoracic aorta and the superior mesenteric artery. Gap 27 also attenuates the endothelium-dependent component of the relaxation induced by ATP in thoracic aorta but did not modify force development in response to PhE[3].

Chemical Properties

Molecular Weight	1304.53
Formula	C₆₀H₁₀₁N₁₅O₁₇
Cas No.	198284-64-9
Smiles	C([C@@H](NC([C@H](CO)N)=O)CCCNC(=N)N)(=O)N1[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC2=CC=CC=C2)C(N[C@H](C(N[C@@H]([C@H](CC)C)C(O)=O)=O)[C@H](CC)C)=O)=O)[C@H](CC)C)=O)[C@@H](C)O)=O)CCCCN)=O)CCC(O)=O)=O)[C@@H](C)O)=O)CCC1
Relative Density.	1.40 g/cm3 (Predicted)
Sequence	Ser-Arg-Pro-Thr-Glu-Lys-Thr-Ile-Phe-Ile-Ile
Sequence Short	SRPTEKTIFII

Storage & Solubility Information

Storage

Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 50 mg/mL (38.33 mM), Sonication is recommended.

H2O: 10 mM, Sonication is recommended.

In Vivo Formulation

10% DMSO+90% Saline: 5 mg/mL (3.83 mM), Solution.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

H2O/DMSO

	1mg	5mg	10mg	50mg
1 mM	0.7666 mL	3.8328 mL	7.6656 mL	38.3280 mL
5 mM	0.1533 mL	0.7666 mL	1.5331 mL	7.6656 mL
10 mM	0.0767 mL	0.3833 mL	0.7666 mL	3.8328 mL

DMSO

	1mg	5mg	10mg	50mg
20 mM	0.0383 mL	0.1916 mL	0.3833 mL	1.9164 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 µL Tween 80 and mix well until fully clarified.

3) Add 450 µL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc